TY - JOUR AU - Marzolini, C. AU - Telenti, A. AU - Decosterd, L. A. AU - Greub, G. AU - Biollaz, J. AU - Buclin, T. PY - 2001 DA - 2001// TI - Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients JO - AIDS VL - 15 UR - https://doi.org/10.1097/00002030-200101050-00011 DO - 10.1097/00002030-200101050-00011 ID - Marzolini2001 ER - TY - JOUR AU - Scourfield, A. AU - Zheng, J. AU - Chinthapalli, S. PY - 2012 DA - 2012// TI - Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals JO - AIDS VL - 26 UR - https://doi.org/10.1097/QAD.0b013e328353b047 DO - 10.1097/QAD.0b013e328353b047 ID - Scourfield2012 ER - TY - JOUR AU - Ward, D. J. AU - Curtin, J. M. PY - 2006 DA - 2006// TI - Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles JO - AIDS Patient Care STDS VL - 20 UR - https://doi.org/10.1089/apc.2006.20.542 DO - 10.1089/apc.2006.20.542 ID - Ward2006 ER - TY - STD TI - Guidelines for Antiretroviral Therapy in Zimbabwe. The National Drug and Therapeutics Policy Advisory Committee (NDTPAC) and The AIDS and TB Unit, Ministry of Health and Child Welfare (MOHCW), Harare, Republic of Zimbabwe. 2010 ID - ref4 ER - TY - JOUR AU - Gatanaga, H. AU - Hayashida, T. AU - Tsuchiya, K. AU - Yoshino, M. AU - Kuwahara, T. AU - Tsukada, H. PY - 2007 DA - 2007// TI - Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26 JO - Clin Infect Dis VL - 45 UR - https://doi.org/10.1086/522175 DO - 10.1086/522175 ID - Gatanaga2007 ER - TY - JOUR AU - Van Luin, M. AU - Gras, L. AU - Richter, C. PY - 2009 DA - 2009// TI - Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations JO - J Acquir Immune Defic Syndr VL - 52 UR - https://doi.org/10.1097/QAI.0b013e3181b061e6 DO - 10.1097/QAI.0b013e3181b061e6 ID - Van Luin2009 ER - TY - JOUR AU - Figueroa, S. AU - Iglesias Gomez, A. AU - Sanchez Martin, A. PY - 2010 DA - 2010// TI - Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV JO - Clin Drug Investig VL - 30 UR - https://doi.org/10.1007/BF03256910 DO - 10.1007/BF03256910 ID - Figueroa2010 ER - TY - STD TI - Puls R. Encore1 Study Group. A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial. In 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3; Kuala Lumpur. 2013; Abstract WELBB01 ID - ref8 ER - TY - STD TI - World Health Organization. WHO Report. Global Tuberculosis Control: Country Profile: South Africa. [apps.who.int/iris/bitstream/10665/44728/1/9789241564380_eng.pdf] UR - http://apps.who.int/iris/bitstream/10665/44728/1/9789241564380_eng.pdf ID - ref9 ER - TY - STD TI - Ministry of Health and Child Welfare Zimbabwe National HIV Estimates. 2010. ID - ref10 ER - TY - JOUR AU - Arab-Alameddine, M. AU - Di Iulio, J. AU - Buclin, T. AU - Rotger, M. AU - Lubomirov, R. AU - Cavassini, M. PY - 2009 DA - 2009// TI - Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals JO - Clin Pharmacol Ther VL - 85 UR - https://doi.org/10.1038/clpt.2008.271 DO - 10.1038/clpt.2008.271 ID - Arab-Alameddine2009 ER - TY - JOUR AU - Ribaudo, H. J. AU - Liu, H. AU - Schwab, M. AU - Schaeffeler, E. AU - Eichelbaum, M. AU - Motsinger-Reif, A. A. PY - 2010 DA - 2010// TI - Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study JO - J Infect Dis VL - 202 UR - https://doi.org/10.1086/655470 DO - 10.1086/655470 ID - Ribaudo2010 ER - TY - JOUR AU - Mukonzo, J. K. AU - Roshammar, D. AU - Waako, P. PY - 2009 DA - 2009// TI - A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans JO - Br J Clin Pharmacol VL - 68 UR - https://doi.org/10.1111/j.1365-2125.2009.03516.x DO - 10.1111/j.1365-2125.2009.03516.x ID - Mukonzo2009 ER - TY - JOUR AU - Elens, L. AU - Vandercam, B. AU - Yombi, J. C. AU - Lison, D. AU - Wallemacq, P. PY - 2010 DA - 2010// TI - Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients JO - Pharmacogenomics VL - 11 UR - https://doi.org/10.2217/pgs.10.94 DO - 10.2217/pgs.10.94 ID - Elens2010 ER - TY - JOUR AU - Ward, B. A. AU - Gorski, J. C. AU - Jones, D. R. AU - Hall, S. D. AU - Flockhart, D. A. AU - Desta, Z. PY - 2003 DA - 2003// TI - The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity JO - J Pharmacol Exp Ther VL - 306 UR - https://doi.org/10.1124/jpet.103.049601 DO - 10.1124/jpet.103.049601 ID - Ward2003 ER - TY - JOUR AU - Di Iulio, J. AU - Fayet, A. AU - Arab-Alameddine, M. AU - Rotger, M. AU - Lubomirov, R. AU - Cavassini, M. PY - 2009 DA - 2009// TI - In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function JO - Pharmacogenet Genomics VL - 19 UR - https://doi.org/10.1097/FPC.0b013e328328d577 DO - 10.1097/FPC.0b013e328328d577 ID - Di Iulio2009 ER - TY - JOUR AU - Winzer, R. L. P. AU - Zilly, M. AU - Tollmann, F. AU - Schubert, J. AU - Klinker, H. W. B. PY - 2003 DA - 2003// TI - No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment JO - Eur J Med Res VL - 8 ID - Winzer2003 ER - TY - JOUR AU - Dirson, G. AU - Fernandez, C. AU - Hindlet, P. AU - Roux, F. AU - German-Fattal, M. AU - Gimenez, F. PY - 2006 DA - 2006// TI - Efavirenz does not interact with the ABCB1 transporter at the blood–brain barrier JO - Pharm Res VL - 23 UR - https://doi.org/10.1007/s11095-006-0279-5 DO - 10.1007/s11095-006-0279-5 ID - Dirson2006 ER - TY - JOUR AU - Zanger, U. M. AU - Klein, K. AU - Saussele, T. AU - Blievernicht, J. AU - Hofmann, M. H. PY - 2007 DA - 2007// TI - Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance JO - Pharmacogenomics VL - 8 UR - https://doi.org/10.2217/14622416.8.7.743 DO - 10.2217/14622416.8.7.743 ID - Zanger2007 ER - TY - STD TI - Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, Shioda T, Khusmith S: Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Research and Therapy 2010; 7. ID - ref20 ER - TY - JOUR AU - Tsuchiya, K. AU - Gatanaga, H. AU - Tachikawa, N. AU - Teruya, K. AU - Kikuchi, Y. AU - Yoshino, M. PY - 2004 DA - 2004// TI - Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens JO - Biochem Biophys Res Commun VL - 319 UR - https://doi.org/10.1016/j.bbrc.2004.05.116 DO - 10.1016/j.bbrc.2004.05.116 ID - Tsuchiya2004 ER - TY - STD TI - Rotger M: CYP2B6: Explaining Efavirenz Pharmacokinetics. HIV Pharmacogenetics 2007; 2. ID - ref22 ER - TY - JOUR AU - Haas, D. W. AU - Ribaudo, H. J. AU - Kim, R. B. AU - Tierney, C. AU - Wilkinson, G. R. AU - Gulick, R. M. PY - 2004 DA - 2004// TI - Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study JO - AIDS VL - 18 ID - Haas2004 ER - TY - JOUR AU - Maimbo, M. AU - Kiyotani, K. AU - Mushiroda, T. AU - Masimirembwa, C. AU - Nakamura, Y. PY - 2012 DA - 2012// TI - CYP2B6 genotype is a strong predictor of systemic exposure 5 to efavirenz in HIV-infected Zimbabweans JO - Eur J Clin Pharmacol VL - 68 UR - https://doi.org/10.1007/s00228-011-1118-0 DO - 10.1007/s00228-011-1118-0 ID - Maimbo2012 ER - TY - JOUR AU - Kwara, A. AU - Lartey, M. AU - Sagoe, K. W. AU - Kenu, E. AU - Court, M. H. PY - 2009 DA - 2009// TI - CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients JO - AIDS VL - 23 UR - https://doi.org/10.1097/QAD.0b013e3283319908 DO - 10.1097/QAD.0b013e3283319908 ID - Kwara2009 ER - TY - JOUR AU - Lopez-Cortes, L. F. AU - Ruiz-Valderas, R. AU - Viciana, P. AU - Alarcon-Gonzalez, A. AU - Gomez-Mateos, J. AU - Leon-Jimenez, E. PY - 2002 DA - 2002// TI - Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis JO - Clin Pharmacokinet VL - 41 UR - https://doi.org/10.2165/00003088-200241090-00004 DO - 10.2165/00003088-200241090-00004 ID - Lopez-Cortes2002 ER - TY - JOUR AU - Matteelli, A. AU - Regazzi, M. AU - Villani, P. AU - De Iaco, G. AU - Cusato, M. AU - Carvalho, A. C. PY - 2007 DA - 2007// TI - Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients JO - Curr HIV Res VL - 5 UR - https://doi.org/10.2174/157016207780636588 DO - 10.2174/157016207780636588 ID - Matteelli2007 ER - TY - JOUR AU - Brennan-Benson, P. AU - Lyus, R. AU - Harrison, T. AU - Pakianathan, M. AU - Macallan, D. PY - 2005 DA - 2005// TI - Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all JO - AIDS VL - 19 UR - https://doi.org/10.1097/01.aids.0000183519.45137.a6 DO - 10.1097/01.aids.0000183519.45137.a6 ID - Brennan-Benson2005 ER - TY - JOUR AU - Friedland, G. AU - Khoo, S. AU - Jack, C. PY - 2006 DA - 2006// TI - Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV JO - J Antimicrob Chemother VL - 58 UR - https://doi.org/10.1093/jac/dkl399 DO - 10.1093/jac/dkl399 ID - Friedland2006 ER - TY - JOUR AU - Desta, Z. AU - Soukhova, N. V. AU - Flockhart, D. A. PY - 2001 DA - 2001// TI - Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A JO - Antimicrob Agents Chemother VL - 45 UR - https://doi.org/10.1128/AAC.45.2.382-392.2001 DO - 10.1128/AAC.45.2.382-392.2001 ID - Desta2001 ER - TY - JOUR AU - Nishimura, Y. AU - Kurata, N. AU - Sakurai, E. AU - Yasuhara, H. PY - 2004 DA - 2004// TI - Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities JO - J Pharmacol Sci VL - 96 UR - https://doi.org/10.1254/jphs.FP0040296 DO - 10.1254/jphs.FP0040296 ID - Nishimura2004 ER - TY - JOUR AU - Dhoro, M. AU - Ngara, B. AU - Kadzirange, G. AU - Nhachi, C. AU - Masimirembwa, C. PY - 2013 DA - 2013// TI - Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe JO - Curr HIV Res VL - 11 UR - https://doi.org/10.2174/1570162X113119990048 DO - 10.2174/1570162X113119990048 ID - Dhoro2013 ER - TY - JOUR AU - Gutierrez, F. AU - Navarro, A. AU - Padilla, S. PY - 2005 DA - 2005// TI - Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring JO - Clin Infect Dis VL - 41 UR - https://doi.org/10.1086/497835 DO - 10.1086/497835 ID - Gutierrez2005 ER - TY - STD TI - Division of aids table for grading the severity of adult and pediatric adverse events. 2004. ID - ref34 ER - TY - JOUR AU - Nyakutira, C. AU - Roshammar, D. AU - Chigutsa, E. AU - Chonzi, P. AU - Ashton, M. AU - Nhachi, C. PY - 2007 DA - 2007// TI - High prevalence of the CYP2B6 516G>T (asterisk 6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe JO - Eur J Clin Pharmacol VL - 64 UR - https://doi.org/10.1007/s00228-007-0412-3 DO - 10.1007/s00228-007-0412-3 ID - Nyakutira2007 ER - TY - JOUR AU - Karlsson, M. O. AU - Sheiner, L. B. PY - 1993 DA - 1993// TI - The importance of modeling interoccasion variability in population pharmacokinetic analyses JO - J Pharmacokinet Biopharm VL - 21 UR - https://doi.org/10.1007/BF01113502 DO - 10.1007/BF01113502 ID - Karlsson1993 ER - TY - JOUR AU - Nyakutira, C. AU - Roshammar, D. AU - Chigutsa, E. AU - Chonzi, P. AU - Ashton, M. AU - Nhachi, C. PY - 2008 DA - 2008// TI - High prevalence of the CYP2B6 516GT(asterisk 6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe JO - Eur J Clin Pharmacol VL - 64 UR - https://doi.org/10.1007/s00228-007-0412-3 DO - 10.1007/s00228-007-0412-3 ID - Nyakutira2008 ER - TY - JOUR AU - Wahlby, U. AU - Jonsson, E. N. AU - Karlsson, M. O. PY - 2001 DA - 2001// TI - Assessment of actual significance levels for covariate effects in NONMEM JO - J Pharmacokinet Pharmacodyn VL - 28 UR - https://doi.org/10.1023/A:1011527125570 DO - 10.1023/A:1011527125570 ID - Wahlby2001 ER - TY - JOUR AU - Wyen, C. AU - Hendra, H. AU - Vogel, M. AU - Hoffmann, C. AU - Knechten, H. AU - Brockmeyer, N. H. PY - 2008 DA - 2008// TI - Impact of CYP2B6 983 T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients JO - J Antimicrob Chemother VL - 61 UR - https://doi.org/10.1093/jac/dkn029 DO - 10.1093/jac/dkn029 ID - Wyen2008 ER - TY - JOUR AU - Rotger, M. AU - Tegude, H. AU - Colombo, S. AU - Cavassini, M. AU - Furrer, H. AU - Decosterd, L. PY - 2007 DA - 2007// TI - Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals JO - Clin Pharmacol Ther VL - 81 UR - https://doi.org/10.1038/sj.clpt.6100072 DO - 10.1038/sj.clpt.6100072 ID - Rotger2007 ER - TY - JOUR AU - Rodriguez-Novoa, S. AU - Barreiro, P. AU - Rendon, A. AU - Jimenez-Nacher, I. AU - Gonzalez-Lahoz, J. AU - Soriano, V. PY - 2005 DA - 2005// TI - Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects JO - Clin Infect Dis VL - 40 UR - https://doi.org/10.1086/429327 DO - 10.1086/429327 ID - Rodriguez-Novoa2005 ER - TY - JOUR AU - Nemaura, T. AU - Nhachi, C. AU - Masimirembwa, C. PY - 2012 DA - 2012// TI - Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: Implications for individualising therapy JO - African J Pharm Pharmacol VL - 6 ID - Nemaura2012 ER - TY - JOUR AU - Lamba, V. AU - Lamba, J. AU - Yasuda, K. AU - Strom, S. AU - Davila, J. AU - Hancock, M. L. PY - 2003 DA - 2003// TI - Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression JO - J Pharmacol Exp Ther VL - 307 UR - https://doi.org/10.1124/jpet.103.054866 DO - 10.1124/jpet.103.054866 ID - Lamba2003 ER - TY - JOUR AU - Cohen, K. AU - Meintjes, G. PY - 2010 DA - 2010// TI - Management of individuals requiring antiretroviral therapy and TB treatment JO - Curr Opin HIV AIDS VL - 5 UR - https://doi.org/10.1097/COH.0b013e3283339309 DO - 10.1097/COH.0b013e3283339309 ID - Cohen2010 ER - TY - JOUR AU - Manosuthi, W. AU - Sungkanuparph, S. AU - Tantanathip, P. PY - 2009 DA - 2009// TI - Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin JO - Antimicrob Agents Chemother VL - 53 UR - https://doi.org/10.1128/AAC.00492-09 DO - 10.1128/AAC.00492-09 ID - Manosuthi2009 ER - TY - JOUR AU - Stöhr, W. AU - Back, D. AU - Dunn, D. PY - 2008 DA - 2008// TI - Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication JO - Antivir Ther VL - 13 ID - Stöhr2008 ER - TY - JOUR AU - Csajka, C. AU - Marzolini, C. AU - Fattinger, K. AU - Decosterd, L. A. AU - Fellay, J. AU - Telenti, A. PY - 2003 DA - 2003// TI - Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection JO - Clin Pharmacol Ther VL - 73 UR - https://doi.org/10.1067/mcp.2003.22 DO - 10.1067/mcp.2003.22 ID - Csajka2003 ER - TY - JOUR AU - Haas, D. W. AU - Smeaton, L. M. AU - Shafer, R. W. AU - Robbins, G. K. AU - Morse, G. D. AU - Labbe, L. PY - 2005 DA - 2005// TI - Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study JO - J Infect Dis VL - 192 UR - https://doi.org/10.1086/497610 DO - 10.1086/497610 ID - Haas2005 ER - TY - JOUR AU - Clifford, D. B. AU - Evans, S. AU - Yang, Y. AU - Acosta, E. P. AU - Ribaudo, H. PY - 2009 DA - 2009// TI - Team* aRMGAsS: Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097 s) JO - HIV Clin Trials VL - 10 UR - https://doi.org/10.1310/hct1006-343 DO - 10.1310/hct1006-343 ID - Clifford2009 ER - TY - JOUR AU - Cabrera, S. E. AU - Santos, D. AU - Valverde, M. P. AU - Dominguez-Gil, A. AU - Gonzalez, F. AU - Luna, G. PY - 2009 DA - 2009// TI - Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients JO - Antimicrob Agents Chemother VL - 53 UR - https://doi.org/10.1128/AAC.01537-08 DO - 10.1128/AAC.01537-08 ID - Cabrera2009 ER - TY - JOUR AU - Rekic, D. AU - Roshammar, D. AU - Mukonzo, J. AU - Ashton, M. PY - 2011 DA - 2011// TI - In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype JO - Br J Clin Pharmacol VL - 71 UR - https://doi.org/10.1111/j.1365-2125.2010.03883.x DO - 10.1111/j.1365-2125.2010.03883.x ID - Rekic2011 ER - TY - JOUR AU - Thompson, M. A. AU - Aberg, J. A. AU - Hoy, J. F. PY - 2012 DA - 2012// TI - Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel JO - JAMA VL - 308 ID - Thompson2012 ER -